Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL

In a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination of the BCL-2 inhibitor, venetoclax (ABT-199/GDC-0199), and monoclonal anti-CD20 antibody, rituximab, showed a tolerable safety profile and induced deep and durable responses, with 41% of patients achieving complete response (CR).

Presented by Andrew Roberts, MB BS, PhD, FRCPA, FRACP, Royal Melbourne Hospital, Melbourne, Australia, at the 20th Congress of the European Hematology Association (EHA)

Year of Production:
Running Time:


Comments are closed.